Literature DB >> 27914292

Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects.

Lauren Lepow1, David A Luckenbaugh1, Lawrence Park1, Ioline D Henter1, Carlos A Zarate2.   

Abstract

Entities:  

Keywords:  Antidepressant; Depression; Glutamate; Ketamine; Memantine; NMDA receptor antagonist

Mesh：

Substances：

Year:  2016        PMID： 27914292      PMCID： PMC5272869          DOI： 10.1016/j.jpsychires.2016.10.023

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN： 0022-3956            Impact factor:   4.791


× No keyword cloud information.
  9 in total

1.  A double-blind, placebo-controlled study of memantine in the treatment of major depression.

Authors:  Carlos A Zarate; Jaskaran B Singh; Jorge A Quiroz; Georgette De Jesus; Kirk K Denicoff; David A Luckenbaugh; Husseini K Manji; Dennis S Charney
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  What Are We Learning From Early-Phase Clinical Trials With Glutamate Targeting Medications for the Treatment of Major Depressive Disorder.

Authors:  Gerard Sanacora
Journal:  JAMA Psychiatry       Date:  2016-07-01       Impact factor: 21.596

3.  Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study.

Authors:  Lobna Ibrahim; Nancy Diazgranados; Jose Franco-Chaves; Nancy Brutsche; Ioline D Henter; Phillip Kronstein; Ruin Moaddel; Irving Wainer; David A Luckenbaugh; Husseini K Manji; Carlos A Zarate
Journal:  Neuropsychopharmacology       Date:  2012-02-01       Impact factor: 7.853

4.  Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories.

Authors:  T Kishimoto; J M Chawla; K Hagi; C A Zarate; J M Kane; M Bauer; C U Correll
Journal:  Psychol Med       Date:  2016-02-12       Impact factor: 7.723

5.  A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression.

Authors:  Carlos A Zarate; Daniel Mathews; Lobna Ibrahim; Jose Franco Chaves; Craig Marquardt; Immaculata Ukoh; Libby Jolkovsky; Nancy E Brutsche; Mark A Smith; David A Luckenbaugh
Journal:  Biol Psychiatry       Date:  2012-12-01       Impact factor: 13.382

Review 6.  Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders.

Authors:  Gerard Sanacora; Carlos A Zarate; John H Krystal; Husseini K Manji
Journal:  Nat Rev Drug Discov       Date:  2008-05       Impact factor: 84.694

7.  Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants.

Authors:  Ronald S Duman; George K Aghajanian; Gerard Sanacora; John H Krystal
Journal:  Nat Med       Date:  2016-03       Impact factor: 53.440

8.  NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses.

Authors:  Anita E Autry; Megumi Adachi; Elena Nosyreva; Elisa S Na; Maarten F Los; Peng-fei Cheng; Ege T Kavalali; Lisa M Monteggia
Journal:  Nature       Date:  2011-06-15       Impact factor: 49.962

9.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites.

Authors:  Panos Zanos; Ruin Moaddel; Patrick J Morris; Polymnia Georgiou; Jonathan Fischell; Greg I Elmer; Manickavasagom Alkondon; Peixiong Yuan; Heather J Pribut; Nagendra S Singh; Katina S S Dossou; Yuhong Fang; Xi-Ping Huang; Cheryl L Mayo; Irving W Wainer; Edson X Albuquerque; Scott M Thompson; Craig J Thomas; Carlos A Zarate; Todd D Gould
Journal:  Nature       Date:  2016-05-04       Impact factor: 49.962
  9 in total
  2 in total

Review 1.  Intrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review.

Authors:  Ilya Demchenko; Vanessa K Tassone; Sidney H Kennedy; Katharine Dunlop; Venkat Bhat
Journal:  Front Psychiatry       Date:  2022-05-26       Impact factor: 5.435

Review 2.  Novel drug developmental strategies for treatment-resistant depression.

Authors:  Éva Borbély; Mária Simon; Eberhard Fuchs; Ove Wiborg; Boldizsár Czéh; Zsuzsanna Helyes
Journal:  Br J Pharmacol       Date:  2022-01-26       Impact factor: 9.473
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.